2025-12-19 - Analysis Report
Here's a comprehensive analysis of Intuitive Surgical (ISRG) based on the provided data.

**0) Simple Numbers First**

*   ISRG Cumulative Return: 107.68%
*   VOO (S&P 500) Cumulative Return: 99.09%
*   ISRG Current Price: $561.89
*   5-day SMA: 555.03
*   20-day SMA: 563.07
*   60-day SMA: 520.55
*   RSI: 43.00
*   PPO: -0.57
*   Expected Return: 28.5%
*   Analyst Consensus: Buy (Mean: 2.06)
*   Target Price: $598.57 (average)

**1) Return Rate Comparison and Alpha/Beta Analysis**

*   **Company Overview:** Intuitive Surgical Inc. develops, manufactures, and markets the da Vinci surgical system and related instruments and accessories.
*   **Return Divergence:** ISRG has outperformed the S&P 500 (VOO). The current divergence in cumulative return is 5.2% (ISRG is ahead). The relative divergence of 31.5 indicates that the current divergence is positioned within the lower third of its historical fluctuation range.

*   **Alpha/Beta Analysis:**

    *   **CAGR:** The Compound Annual Growth Rate (CAGR) has varied significantly, with high growth in the 2015-2019 period, followed by negative growth in 2018-2022, and a recent resurgence.
    *   **MDD:** The Maximum Drawdown (MDD) remains consistently high, indicating significant potential for price declines.
    *   **Alpha:** Alpha, representing excess return relative to the market, was strong in the early periods but has been negative more recently, suggesting underperformance relative to market risk.  It shows a positive uptick in the most recent periods.
    *   **Beta:** Beta has generally increased over time, indicating that ISRG's price is becoming more sensitive to market movements. The beta figures are unusual (negative in some years, significantly greater than 1 in others), implying that during those specific periods, the stock was either negatively correlated or extremely sensitive to market movements.
    *   **Cap(B):** The market capitalization grew significantly through 2023, but fluctuated more recently.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** $561.89. Up slightly from the previous close.
*   **Moving Averages:** The 5-day SMA is below the 20-day SMA, which is slightly above the current price, while the 60-day SMA is significantly lower. This suggests a short-term upward trend (5-day moving up), but potential resistance at the 20-day SMA. The fact that both are above the 60-day SMA suggests a longer-term upward trend.

**3) Indicator Analysis**

*   **MRI:** The Market Risk Indicator (MRI) of 0.7 suggests medium investment risk.
*   **RSI:** An RSI of 43.00 indicates the stock is neither overbought nor oversold, suggesting a neutral momentum.
*   **PPO:** A PPO of -0.57 signals the stock is slightly below its moving average, hinting at a possible buying opportunity.
*   **Hybrid Signal:** The hybrid signal suggests a "Buy" recommendation with 100% of cash allocation.
*   **Divergence Change:** The recent (20-day) relative divergence change of 0.0 indicates a short-term downtrend.
*   **Expected Return:** The Expected Return of 28.5% suggests strong potential long-term gains compared to the S&P 500.

**4) Recent News & Significant Events**

*   **Positive Analyst Outlook:** Truist Financial raised the price target for ISRG, indicating a positive outlook.
*   **Analyst Forecasts:** Several articles discuss analyst forecasts for ISRG, with some highlighting key catalysts for future growth.
*   **Stock Performance:** An article notes ISRG's recent positive performance, suggesting positive market sentiment.
*   **Competitive Landscape:** One article compares ISRG to Medtronic (MDT), highlighting the competitive dynamics in the robotic surgery market.
*   **Technical Analysis:** An article suggests ISRG is hitting a key support level, potentially indicating a buying opportunity.

**4-2) Analyst Opinions**

*   **Consensus:** The analyst consensus is a "Buy" with a mean rating of 2.06.
*   **Target Price:** The average target price is $598.57, implying potential upside from the current price.
*   **Recent Rating Changes:** No recent rating changes are indicated.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-10-22 | 1.98  | 2.51 B$   |
| 2025-07-23 | 1.84  | 2.44 B$   |
| 2025-04-23 | 1.95  | 2.25 B$   |
| 2024-10-18 | 1.59  | 2.04 B$   |
| 2025-10-22 | 1.59  | 2.04 B$   |

*   **EPS Trend:** Earnings Per Share (EPS) has shown a positive trend over the last few quarters, indicating improved profitability. However, the duplicate entry of 2025-10-22 with EPS 1.59 should be reviewed for accuracy.
*   **Revenue Trend:** Revenue has also shown a consistent upward trend, demonstrating strong sales growth.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $2.51B    | 66.36%        |
| 2025-06-30   | $2.44B    | 66.31%        |
| 2025-03-31   | $2.25B    | 64.69%        |
| 2024-12-31   | $2.41B    | 68.04%        |
| 2024-09-30   | $2.04B    | 67.41%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE    |
|--------------|-----------|--------|
| 2025-09-30   | $16.93B   | 4.16%  |
| 2025-06-30   | $17.85B   | 3.69%  |
| 2025-03-31   | $17.11B   | 4.08%  |
| 2024-12-31   | $16.43B   | 4.17%  |
| 2024-09-30   | $15.58B   | 3.63%  |

*   **Revenue Growth:** Consistent increase in quarterly revenue, indicating strong demand for Intuitive Surgical's products.
*   **Profit Margin:** Consistently high profit margins above 64%, reflecting strong pricing power and efficient operations.
*   **Equity:** Increasing equity, reflecting the accumulation of retained earnings.
*   **ROE:** Return on Equity (ROE) has fluctuated, but has remained fairly consistent, reflecting the company's ability to generate profit from shareholders' investments.

**7) Comprehensive Analysis (Summary)**

Intuitive Surgical (ISRG) presents a mixed but generally positive picture.

*   **Strengths:**
    *   **Outperformance:** ISRG has outperformed the S&P 500 over the long term.
    *   **Growth:** Recent earnings and revenue show a strong upward trend.
    *   **Profitability:** High profit margins and strong ROE demonstrate financial health.
    *   **Analyst Sentiment:** Positive analyst ratings and price targets suggest confidence in future performance.
    *   **Innovation:** As a leader in robotic surgery, ISRG benefits from ongoing innovation and adoption of its technology.

*   **Weaknesses/Concerns:**
    *   **Volatility:** High MDD values indicate the potential for significant price declines.
    *   **Market Sensitivity:** Increasing beta may make ISRG more susceptible to market downturns.
    *   **Recent Divergence Downtrend:** A short-term downtrend based on the recent divergence change.
    *   **MRI:** The MRI of 0.7 indicates medium investment risk.

*   **Overall:**
    *   ISRG appears to be a fundamentally strong company with significant growth potential. The positive analyst sentiment, robust financial performance, and leadership position in a growing market are compelling factors. However, investors should be aware of the stock's volatility and sensitivity to market movements. The hybrid signal suggests a "Buy" recommendation, aligning with the analyst consensus.
    *   **Recommendation:** Considering the long-term expected return, positive analyst outlook, and recent financial performance, a buy-and-hold strategy may be appropriate for investors with a higher risk tolerance and a long-term investment horizon. However, given the volatility, it would be prudent to monitor the stock closely and adjust positions as needed.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.